EP2059244A1 - Titration schedule for bifeprunox for treating schizophrenia and kits for use therein - Google Patents
Titration schedule for bifeprunox for treating schizophrenia and kits for use thereinInfo
- Publication number
- EP2059244A1 EP2059244A1 EP07802974A EP07802974A EP2059244A1 EP 2059244 A1 EP2059244 A1 EP 2059244A1 EP 07802974 A EP07802974 A EP 07802974A EP 07802974 A EP07802974 A EP 07802974A EP 2059244 A1 EP2059244 A1 EP 2059244A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bifeprunox
- strength
- titration
- compound
- unit dosages
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004448 titration Methods 0.000 title claims abstract description 96
- 229950009087 bifeprunox Drugs 0.000 title claims abstract description 89
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 201000000980 schizophrenia Diseases 0.000 title description 9
- -1 bifeprunox compound Chemical class 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims description 23
- 238000012423 maintenance Methods 0.000 claims description 14
- ONWKHSGOYGLGPO-UHFFFAOYSA-N methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound CS(O)(=O)=O.C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 ONWKHSGOYGLGPO-UHFFFAOYSA-N 0.000 claims description 14
- 210000003169 central nervous system Anatomy 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 206010029216 Nervousness Diseases 0.000 abstract 1
- 230000001379 nervous effect Effects 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 5
- 206010031127 Orthostatic hypotension Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 208000032140 Sleepiness Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229960001021 lactose monohydrate Drugs 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- IUVSEUFHPNITEQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CN2CCN(CC2)C=2C=3OCCOC=3C=CC=2)=C1 IUVSEUFHPNITEQ-UHFFFAOYSA-N 0.000 description 1
- DJIOGHZNVKFYHH-UHFFFAOYSA-N 2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=CC=CC=N1 DJIOGHZNVKFYHH-UHFFFAOYSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- YVPUUUDAZYFFQT-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one Chemical compound C1CN(C)CCN1C1=CC=CC2=C1OC(=O)N2 YVPUUUDAZYFFQT-UHFFFAOYSA-N 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010050392 Face injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010065508 Orthostatic hypertension Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940100466 mylicon Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021572 root beer Nutrition 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Definitions
- the present invention relates to compositions, kits, and methods for a titration schedule to facilitate the initiation of the treatment of at least one central nervous system (CNS) condition or disorder by administering a plurality of dosage units of a composition comprising a compound 7-[4-([1 ,1'-biphenyl]-3-ylmethyl)-1- piperazinyl]-2(3H)-benzoxazolone monomethane-sulfonate (INN bifeprunox).
- CNS central nervous system
- hydrochloric acid salt of the above-referenced formula i.e., (7-[4- ([1 ,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone, is described and claimed in WO 97/36893 and the monomethanesulfonate salt is described and claimed in WO 02/066449, which are incorporated herein by reference.
- WO 05/016898 describes and claims the different polymorphic forms of bifeprunox mesylate, which is incorporated herein by reference.
- the N-oxide of bifeprunox is described in WO 2007/023141 , which is incorporated herein by reference.
- Bifeprunox (earlier known as DU 127090) binds to dopamine D 2 -like receptors and 5-HT 1A receptors; it is a partial agonist at dopamine D 2 / 3 receptors and also a partial agonist at serotonin 5-HT 1A receptors.
- Bifeprunox's affinity for both the dopamine D 2 and serotonin 5-HT 1A receptors makes it useful for the treatment of schizophrenia and other psychotic disorders.
- bifeprunox can be of value for the treatment of affections or diseases of the CNS caused by disturbances in either the dopamine or serotinergic systems, such as Parkinson's disease, aggression, anxiety disorders, autism, vertigo, depression, bipolar disorder, disturbances of cognition or memory, and further for example, schizophrenia and other psychotic disorders.
- the length of the titration period and the dosages used and the increments thereof are, however, drug-dependent. Therefore, there is a need to find a suitable titration schedule for safe and effective inititiation of the treatment with bifeprunox. It has now been surprisingly discovered that the tolerability to the compound can be improved and the occurrence of at least one of the undesired side effects can be reduced or prevented by gradual increase of the bifeprunox compound dose according to the titration schedule of this invention.
- the present invention is directed to compositions, kits, and methods for a titration schedule to facilitate the initiation of the treatment of at least one CNS condition or disorder by administering a plurality of dosage units comprising the compound 7-[4-([1 , 1 '-biphenyl]-3-ylmethyl)-1 -piperazinyl]-2(3H)-benzoxazolone monomethane-sulfonate (INN bifeprunox).
- the present invention is related to a composition regimen for use in a titration schedule for titrating dosages of the at least one bifeprunox compound over a period of time up to a maintenance dosage for the treatment of at least one central nervous system condition comprising a plurality of unit dosages of a composition, each of the unit dosages comprising at least one bifeprunox compound, wherein period of time of the titration schedule comprises at least six time segments and the dosage of the at least one bifeprunox compound over the entire titration schedule increases in strength each time segment.
- a titration kit comprising at least six sequential unit dosages, each of the unit dosages comprising at least one bifeprunox compound, and wherein the unit dosages are of increasing strengths over the entire titration period.
- the present invention is related to a method for a titration schedule for initiating the treatment at least one central nervous system condition in a subject in need thereof comprising administering to the subject a composition regimen comprising a plurality of unit dosages of the composition, each of the unit dosages comprises at least one bifeprunox compound, wherein the unit dosages over the entire titration schedule increase in amount of the at least one bifeprunox compound.
- a method for reducing at least one side effect associated with the initiation of a bifeprunox treatment comprising administering a composition regimen comprising a plurality of unit dosages of a composition, each of the unit dosages comprises at least one bifeprunox compound according, wherein the unit dosages over the titration schedule increase in an amount of the at least one bifeprunox compound.
- Bifeprunox compounds are indicated for the treatment of CNS disorders including schizophrenia, other psychotic disorders and Parkinson's disease.
- dosage strength are expressed in an amount equivalent to bifeprunox base.
- bifeprunox base refers to the compound 7-[4-([1 ,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxa-zolone (INN
- the typical dosing regimen ranges from amounts equivalent to 0.05 mg to 60 mg bifeprunox base; doses may vary based in part on the severity of the CNS condition and other conditions of the patient.
- a titration schedule dose or a maintenance dose for bifeprunox compounds can be a dose equivalent to 10 mg/day, 20 mg/day, 30 mg/day or 40 mg/day of bifeprunox base.
- the efficacy, safety and tolerability profile of bifeprunox suggests it may be an effective agent to employ as a treatment option for patients with schizophrenia.
- bifeprunox treatment can result in adverse events during initiation of treatment, which may lead to the discontinuation of bifeprunox treatment and/or inconsistent use of the treatment.
- bifeprunox compound(s) refers to the active compound 7-[4-([1 ,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxa-zolone, its N- oxide and pharmaceutically acceptable salts, solvates and hydrates thereof and solvates and hydrates of the salts.
- N-oxide When the N-oxide is used as the bifeprunox compound, the amount in milligrams is the same amount as the amount the person skilled in the art would select for the bifeprunox compound without the oxide.
- pharmaceutically acceptable salts of bifeprunox or its N-oxide may be obtained using standard procedures well known in the art, for example, by mixing a compound of the present invention with a suitable acid, for instance an inorganic acid or an organic acid.
- the at least one bifeprunox compound comprises bifeprunox mesylate.
- the at least one bifeprunox compound is bifeprunox mesylate.
- the bifeprunox mesylate may be chosen from the ⁇ , Y, or ⁇ crystalline polymorphic forms, and mixtures thereof.
- the at least one bifeprunox compound comprises at least one polymorphic form chosen from the ⁇ and Y polymorphic forms.
- the crystalline polymorphic form of ⁇ bifeprunox mesylate according to the present disclosure (which is the preferred polymorphic form) is defined by at least the physicochemical parameters as disclosed in WO 2005/016898.
- the term "titration schedule" refers to a regimen of dosages of a pharmaceutically active agent over a period of time, based in part on a target dose and/or a maintenance dose.
- the target dose and/or maintenance dose can be a dose equivalent to at least 10 mg/day, at least 20 mg/day, at least 30 mg/day or at least 40 mg/day of bifeprunox base and, for example, 10 mg/day, 20 mg/day, 30 mg/day or 40 mg/day of bifeprunox base.
- a target dose is 20 mg/day of at least one bifeprunox compound.
- the target dose is 40 mg/day of at least one bifeprunox compound.
- the bifeprunox compound administered in the form of a plurality of unit dosages of a composition can be over the course of a period chosen from 6 to 14 consecutive days, such as 6 to 10 days and further for example, from 6 to 8 days and in particular seven days.
- the period of time can be divided into time segments other than one day, such as two or three days segments.
- the same unit dosage of bifeprunox compound can be administered every day within the time segment, wherein the administration may be once daily the full dosage, but also, for example, twice daily half of the dosage.
- the period over which the titration schedule spans may be in part due to the lowest dose with which the titration starts, the amount of increase considered clinically acceptable and the target and/or maintenance dose; for example, a titration schedule may span over a larger number of days (such as 14 days) it may span over a shorter period of time (such as 6 or 7 days). Therefore an embodiment of the present invention is a titration schedule wherein the number of time segments is at least six and with a titration period of at least six, twelve or eighteen days, respectively. Another embodiment relates to is a titration schedule wherein the number of time segments is at least seven and with a titration period of at least seven, fourteen or twenty one days, respectively.
- the strength or amount of bifeprunox compound in each unit dosage increases incrementally over the subsequent titration schedule until a target dose and/or maintenance dose is reached.
- consecutive strengths or amounts of unit dosages may be given during the course of the titration such that over the entire titration schedule, an overall increase in strength or amount of the unit dosage results. For example, comparing the first unit dose to the last unit dose before the maintenance unit dosage is administered, there is an increase in the amount of bifeprunox compound being administered.
- each of the unit dosages of the composition are chosen from single strength doses equivalent to bifeprunox base from about 0.05 mg to about 0.07 mg, from about 0.07 mg to about 0.18 mg, from about 0.18 mg to about 0.35 mg, from about 0.35 mg to about 0.70 mg, from about 0.70 mg to about 1.4 mg, from about 1.4 mg to about 3.5 mg, from about 3.5 mg to about 7.0 mg, from about 7 mg to about 14 mg, and from about 14 mg to about 28 mg.
- the strength can be subsequent strengths within the group indicated above.
- each of the unit dosages of the compositions are chosen from about 0.0550 mg to about 0.0675 mg, from about 0.10 mg to about 0.15 mg, from about 0.20 mg to about 0.30 mg, from about 0.4 mg to about 0.6 mg, from about 0.8 mg to about 1.2 mg, from about 1.5 mg to about 2.5 mg, from about 4.0 mg to about 6.0 mg, from about 8 mg to about 12 mg, and from about 15 mg to about 25 mg of a bifeprunox compound.
- the strength can be subsequent strengths within the group indicated above.
- the strength or amount of each unit dosage may be chosen from single strength doses equivalent to bifeprunox base about 0,0625 mg, 0.125 mg, about 0.25 mg, about 0.5 mg, about 1.0 mg, about 2.0 mg, about 5.0 mg, about 10 mg and about 20 mg.
- the unit dosages may increase in an amount or strength of the bifeprunox compound ranging from about 1.5 to 3 times that of the preceding dose and further for example, from about 2 to 2.5 times that of the preceding dose.
- a preceding dosage is available for consideration.
- composition regimen provided in the present disclosure can be in the form of a kit comprising, e.g., a plurality of unit dosages in the form of tablets for the titration schedule to arrive at the final and/or maintenance dose.
- the present invention is further directed to a kit for a titration schedule to facilitate the treatment of at least one central nervous system condition comprising a plurality of unit dosages of a composition comprising at least one bifeprunox compound, wherein the unit dosages over the titration schedule increase in an amount of the bifeprunox compound.
- An embodiment therefore relates to a titration kit, comprising at least six sequential unit dosages, each of the unit dosages comprising at least one bifeprunox compound, wherein the unit dosages are of increasing strengths over the entire titration period.
- the strengths or amounts of each unit dosage can be chosen from the groups of different strengths indicated above.
- the titration period of the kit is divided in at least six time segments (as defined previously).
- the kit as described above can be in the form of a package, such as a blister package, the package comprising a plurality of tablets, e.g., each tablet having a different dose than another tablet and further for example, having indicia disposed adjacent to the tablets for displaying successive strengths and/or successive days.
- a package such as a blister package
- the package comprising a plurality of tablets, e.g., each tablet having a different dose than another tablet and further for example, having indicia disposed adjacent to the tablets for displaying successive strengths and/or successive days.
- the kit can be in the form a package comprising a plurality of capsules, granular aerosols, suppositories and/or suspensions to form each unit dosage.
- dosage forms can be prepared by mixing, individually or together, the polymorphic forms of the bifeprunox compound (e.g., ⁇ , ⁇ and/or ⁇ of bifeprunox mesylate) with inert pharmaceutically acceptable excipients, carriers and/or pharmaceutically acceptable ingredients.
- the active ingredients i.e., a bifeprunox compound
- the active ingredients may be mixed with solid, powdered ingredients, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
- the mixture may then be processed into granules, pressed into tablets, and/or any other known pharmaceutical form such as suppositories and/or suspensions.
- Soft gelatin capsules may further be prepared containing a composition comprising a mixture of the active ingredients of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules.
- Hard gelatin capsules may contain granules of the active ingredients.
- Hard gelatin capsules may also contain the active ingredients in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin.
- compositions of the present disclosure can comprise at least one pharmaceutical excipient.
- suitable excipients include suspending agents (for example, gums, xanthans, cellulosics and sugars), humectants (for example, sorbitol), solubilizers (for example, ethanol, water, PEG and propylene glycol), surfactants (for example, sodium lauryl sulfate, Spans, Tweens, and cetyl pyridine), preservatives, antioxidants (for example, parabens, and vitamins E and C), anti-caking agents, coating agents, chelating agents (for example, EDTA), stabilizers, antimicrobial agents, antifungal or antibacterial agents (for example, parabens, chlorobutanol, phenol, sorbic acid), isotonic agents (for example, sugar, sodium chloride), thickening agents (for example, methyl cellulose), flavoring agents (for example, chocolate, thal
- the active ingredients may be separately premixed with the other non- active ingredients, before being mixed to form a formulation.
- the active ingredients may also be mixed with each other, before being mixed with the non-active ingredients to form a formulation.
- Tablets with a strength of 10 mg were prepared according to the following procedures (required quantities for all strengths are given in the Table below): [031] The microcrystalline cellulose was added to bin blender A and mixed for five (5) minutes to distribute. The material was transferred to bin blender B and mixed for five (5) minutes to distribute. The following ingredients were added to bin blender B; half (V-O portion of lactose monohydrate bifeprunox mesylate, sodium starch glycolate and remaining half (V-O portion of lactose monohydrate and mixed for twenty-five (25) to thirty-five (35) minutes.
- the granulation was milled/de-agglomerated with a rotating impeller- screening mill using a conical screen equipped with a 0.6 mm screen or 0.8 mm screen.
- the granulation was transferred to a bin blender A.
- To bin blender A sodium stearyl fumarate and colloidal silicon dioxide (for 20 mg only) was added and sieved through a #20 mesh.
- the granulation was mixed for a target of ten (10) to twenty-five (25) minutes, at 6 to 8 rpm.
- the granulation was compressed on the rotary tablet press and collected in suitable containers.
- Tablets with a strength of 0.25 mg/tablet, 0.5 mg/tablet, 1.0 mg/tablet, 2.0 mg/tablet, 5.0 mg/tablet and 20 mg/tablet were prepared in a corresponding manner by decreasing or increasing the amount of bifeprunox mesylate compensating with the amount of lactose monohydrate and/or microcrystalline cellulose to come to the same final weight, with the understanding that a different coating component was used in order to obtain a different color for every tablet strength (see Table 1 ).
- EXAMPLE 3 CLINICAL STUDY [035] This study represented a randomized, double-blinded, placebo- controlled, sequential panel, rapid titration study of the safety and tolerability of bifeprunox compounds in subjects with schizophrenia. In particular, this study assessed the safety, tolerability and efficacy after a rapid titration of bifeprunox to a therapeutic dose of 40 mg/day in schizophrenia and schizoaffective subjects. Eligible subjects were hospitalized at the start of the screening period and entered a single- blind placebo run-in period (day -7 to -1 ) to assure that the 7-day antipsychotic drug- free criterion was met prior to bifeprunox titration.
- Each listed dose in the titration schedule was administered once daily (QD) followed by the next higher dose the following day. If a subject did not tolerate a given dose, the subject was allowed to repeat that same dose for one extra day before increasing the dose to the next level. Only one repeat dose, however, was allowed during the entire titration period. Upon reaching the high proposed dose of 40 mg/day, the subject entered a 3-day maintenance period for this dose. Final assessments were performed on the day after the last maintenance period dose and follow-up assessments were performed 3 days after the last dose of study treatment.
- Efficacy assessments i.e., Positive and Negative Symptoms of Schizophrenia (PANSS) and Clinical Global Impression-Severity (CGI-S) were performed at screening, Day-1 and at the final assessment; Clinical Global Impressions-Improvement (CGI-I)) was performed at the final assessment only. Safety was monitored throughout the study by assessment of physical examination, vital signs, adverse events (AEs), concomitant medications, clinical laboratory assessments, 12- lead electrocardiograms (ECGs), Simpson-Angus Scale (SAS) score and Barnes
- AAS Akathisia Scale
- the treatment phase lasted approximately two weeks, including follow-up assessment. Subjects remained hospitalized until the post- treatment follow-up assessment was completed or until their condition had clinically stabilized.
- Bifeprunox were tablets taken orally at a total daily dose of 0.25 mg to 40 mg in the following titration schedules:
- Placebo tablets matching the bifeprunox tablets were taken orally using the same dosing regimen as the test product were administered.
- titration schedule 2c appeared to reduce the AEs observed during titration schedule 1 , indicating an advantage with a more gradual increase from 0.25 mg to 10 mg and then up to 40 mg doses using a 7-day rather than 6-day titration schedule.
- All subjects in the bifeprunox group in titration schedule 1 reported at least one treatment of emergent adverse event (TEAE).
- TEAE emergent adverse event
- Adverse events were most commonly reported between 0.25 mg to 10 mg dose levels, particularly at the 5 mg dose.
- the most commonly observed TEAEs were nervous system disorders (somnolence, dizziness, headache NOS and gait abnormal NOS), and gastrointestinal disorders (nausea and vomiting).
- Orthostatic hypotension was also reported at the 1 , 5, 10, and 40 mg dose levels. No TEAEs occurred at the 20 mg dose level. All subjects receiving bifeprunox in titration schedule 1 were considered to have at least 1 TEAE which was related to study treatment; all TEAEs occurring in the nervous system were considered to be related to study treatment. Three subjects receiving bifeprunox in titration schedule 1 reported TEAEs which were considered to be severe, with the most commonly reported events occuring in the nervous system. Severe TEAEs of orthostatic hypotension, nausea, vomiting NOS, and rigors were reported. All severe TEAEs occurred at the 1 , 5 and 10 dose levels.
- titration schedule 1 In contrast to titration schedule 1 , fewer subjects reported events of somnolence which were considered to be related to the study treatment, which no TEAEs of anorexia, gait abnormal NOS or orthostatic hypotension were reported. Three subjects receiving bifeprunox in titration schedule 2c reported TEAEs which were considered to be severe. All three subjects reported severe TEAEs of dizziness and a severe TEAE of pallor was reported in one subject. All severe TEAEs occurred at the 2 mg and 5 mg dose level. One subject, receiving placebo in titration schedule 2c, reported an serious adverse event (SAE) (face injury).
- SAE serious adverse event
- titration schedule 1 Subjects in titration schedule 1 received bifeprunox at doses of 0.25, 1 , 5,10,20, and 40 mg over 6 consecutive days. In this titration schedule, most AEs occurred in the 0.25 to 10 mg dose range. Once the 10 mg dose was reached, daily increases to 20 to 40 mg were well-tolerated. Titration schedule 2c had a slower titration up to the 10 mg level with subjects dosed at 0.25, 0.5, 2, 5, 10, 20, and 40 mg bifeprunox over 7 consecutive days. This longer and more conservative titration schedule resulted in fewer withdrawals from the study due to intolerable effects and appeared to reduce the AEs observed during titration schedule 1.
- Bifeprunox exposure was approximately 1.3 to 1.5 times higher in titration schedule 2c than titration schedule 1 on the final study day, while exposure was comparable between the 2 schedules for the metabolites.
- the results of this study generally indicated that titration of bifeprunox from 0.25 mg to 40 mg over 7 days was better tolerated than titration over a 6-day period. It, however, should be noted that the final, maintenance dose of this study was 40 mg and the titration schedule, i.e., 6 to 7 days, was based in part on the level of this final, maintenance dose.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07802974A EP2059244A1 (en) | 2006-08-31 | 2007-08-29 | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84124406P | 2006-08-31 | 2006-08-31 | |
EP06119936 | 2006-08-31 | ||
US84149506P | 2006-09-01 | 2006-09-01 | |
EP06120016 | 2006-09-01 | ||
PCT/EP2007/058957 WO2008025780A1 (en) | 2006-08-31 | 2007-08-29 | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
EP07802974A EP2059244A1 (en) | 2006-08-31 | 2007-08-29 | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2059244A1 true EP2059244A1 (en) | 2009-05-20 |
Family
ID=38704953
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07802974A Withdrawn EP2059244A1 (en) | 2006-08-31 | 2007-08-29 | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
EP07802975A Withdrawn EP2059245A1 (en) | 2006-08-31 | 2007-08-29 | Bifeprunox doses for treating schizophrenia |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07802975A Withdrawn EP2059245A1 (en) | 2006-08-31 | 2007-08-29 | Bifeprunox doses for treating schizophrenia |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2059244A1 (en) |
JP (2) | JP2010501626A (en) |
KR (1) | KR20090063228A (en) |
AU (2) | AU2007291234A1 (en) |
BR (1) | BRPI0715445A2 (en) |
CA (2) | CA2661120A1 (en) |
EA (1) | EA200970239A1 (en) |
IL (1) | IL196867A0 (en) |
NO (1) | NO20091243L (en) |
WO (2) | WO2008025780A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010060742A1 (en) * | 2008-11-03 | 2010-06-03 | Solvay Pharmaceuticals B.V. | Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders |
WO2010070061A1 (en) * | 2008-12-19 | 2010-06-24 | Abbott Healthcare Products B.V. | Compositions, kits and methods of a titration schedule for bifeprunox compounds |
LT2445502T (en) | 2009-06-25 | 2017-09-25 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
WO2011023796A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Healthcare Products B.V. | Bifeprunox for treating addiction |
JP6654042B2 (en) | 2012-09-19 | 2020-02-26 | アルカームス ファーマ アイルランド リミテッド | Pharmaceutical composition with improved storage stability |
EP3119399A4 (en) | 2014-03-20 | 2017-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199801942T2 (en) | 1996-03-29 | 2000-08-21 | Duphar International Research B.V. | Piperazine ve piperidin bile�ikleri. |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
AR034206A1 (en) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | A PROCEDURE FOR THE PREPARATION OF MESILATES OF PIPERAZINE DERIVATIVES AND SUCH MESILATES |
AR045362A1 (en) * | 2003-08-18 | 2005-10-26 | Solvay Pharm Bv | STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA |
US7423040B2 (en) * | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
RU2394821C2 (en) | 2005-08-22 | 2010-07-20 | Солвей Фармасьютикал Б.В. | N-oxides as prodrug of piperazine and piperidine derivatives |
-
2007
- 2007-08-29 BR BRPI0715445-3A patent/BRPI0715445A2/en not_active IP Right Cessation
- 2007-08-29 WO PCT/EP2007/058957 patent/WO2008025780A1/en active Application Filing
- 2007-08-29 AU AU2007291234A patent/AU2007291234A1/en not_active Abandoned
- 2007-08-29 EP EP07802974A patent/EP2059244A1/en not_active Withdrawn
- 2007-08-29 AU AU2007291235A patent/AU2007291235A1/en not_active Abandoned
- 2007-08-29 JP JP2009526089A patent/JP2010501626A/en not_active Withdrawn
- 2007-08-29 EP EP07802975A patent/EP2059245A1/en not_active Withdrawn
- 2007-08-29 CA CA002661120A patent/CA2661120A1/en not_active Abandoned
- 2007-08-29 KR KR1020097006567A patent/KR20090063228A/en not_active Application Discontinuation
- 2007-08-29 EA EA200970239A patent/EA200970239A1/en unknown
- 2007-08-29 JP JP2009526088A patent/JP2010501625A/en not_active Withdrawn
- 2007-08-29 CA CA002661800A patent/CA2661800A1/en not_active Abandoned
- 2007-08-29 WO PCT/EP2007/058958 patent/WO2008025781A1/en active Application Filing
-
2009
- 2009-02-03 IL IL196867A patent/IL196867A0/en unknown
- 2009-03-25 NO NO20091243A patent/NO20091243L/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2008025780A1 * |
Also Published As
Publication number | Publication date |
---|---|
EA200970239A1 (en) | 2009-08-28 |
WO2008025781A1 (en) | 2008-03-06 |
AU2007291235A1 (en) | 2008-03-06 |
JP2010501625A (en) | 2010-01-21 |
AU2007291234A1 (en) | 2008-03-06 |
CA2661800A1 (en) | 2008-03-06 |
NO20091243L (en) | 2009-03-25 |
JP2010501626A (en) | 2010-01-21 |
BRPI0715445A2 (en) | 2014-05-13 |
CA2661120A1 (en) | 2008-03-06 |
WO2008025780A1 (en) | 2008-03-06 |
IL196867A0 (en) | 2009-11-18 |
EP2059245A1 (en) | 2009-05-20 |
KR20090063228A (en) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2021006T3 (en) | USE OF flibanserin in postmenopausal SEXLYSTFORSTYRRELSER | |
US20230201184A1 (en) | Compositions and methods for treating schizophrenia | |
EP2059244A1 (en) | Titration schedule for bifeprunox for treating schizophrenia and kits for use therein | |
EA014189B1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
US20110070319A1 (en) | Bifeprunox doses for treating schizophrenia | |
US20110319384A1 (en) | Pharmaceutical Compositions | |
WO2004054574A1 (en) | Solid drug for oral use | |
US20080026050A1 (en) | Solid dose formulations of a thrombin receptor antagonist | |
TWI646960B (en) | Preparation for inhibition or improvement of progression of chronic kidney disease | |
US20080132520A1 (en) | Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds | |
TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
US3505451A (en) | Compositions and methods for alleviating schizophrenia employing one of haloperidol,trifluperidol or an acid addition salt thereof and one of desipramine,imipramine and an acid addition salt thereof | |
WO2010070061A1 (en) | Compositions, kits and methods of a titration schedule for bifeprunox compounds | |
TW200817390A (en) | Compositions, kits and methods of a titration schedule for bifeprunox compounds | |
WO2008061966A2 (en) | New use of flibanserin | |
US20100022558A1 (en) | Treatment of insomnia | |
EP1518554A1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090331 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090616 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABBOTT HEALTHCARE PRODUCTS B.V. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20090331 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120211 |